On World Sleep Day Idorsia highlights the publication of a global study on the economic and societal impact of chronic insomnia disorder
- Chronic insomnia disorder (CID) is a persistent medical condition that prevents sufferers from getting restorative sleep1-3; research on wider societal and indirect economic costs associated with CID have been limited to date1
- New report indicates annual lost productivity costs of $417 billion in GDP across working age populations in the countries of focus* and annual “hidden” intangible wellbeing losses of $239.5 billion1
- Reducing the impact of CID could result in a boost to the GDP of national economies ranging from 0.64% to 1.31% across the countries of focus*1
- Idorsia partners with the World Sleep Society on educational and disease awareness activities focused on the theme: Sleep is Essential for Health
Allschwil, Switzerland – March 17, 2023
On World Sleep Day, Idorsia Ltd (SIX: IDIA) highlights the publication of a first-of-its-kind report by RAND Europe on the economic and societal impact of chronic insomnia disorder,†
“The Societal and Economic Burden of Insomnia in Adults: An
International Study”. Idorsia commissioned RAND Europe, an independent, not-for-profit policy research organization, to help fill some of the knowledge gaps associated with understanding the
financial burden of chronic insomnia disorder and to deliver new peer-reviewed research into the impacts of insomnia.
The new report focuses on both the indirect economic costs (i.e., non-healthcare related costs) and the “hidden” intangible costs (i.e., costs that are not directly observed through economic transactions but nonetheless have impacts on an individual’s health or well-being) associated with chronic insomnia disorder.
RAND Europe’s findings indicate the indirect economic costs associated with lost work productivity ranging between $1.8 billion and $207.5 billion (for a total of $417 billion) in gross domestic product (GDP) across the countries RAND analyzed.*1 The intangible annual wellbeing losses range from $1.5 billion and $127.1 billion (for a total of $239.5 billion) in the countries of focus, which include France, Italy, Germany, Spain, the United Kingdom, the United States, and Canada.1,2 The report also provided additional insights on chronic insomnia disorder.